ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35089
0,01%
Bitcoin
66.301,72
-0,51%
Brent Oil
82,065
-0,07%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Biontech Se (0A3M)

  7. Biontech Se (0A3M) Notícias

0A3M

Biontech (0A3M)

Biontech Se
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:LSE:0A3M
DataHoraFonteTítuloCódigoCompanhia
01/06/202411:00UK RegulatoryPhase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem LungenkarzinomLSE:0A3MBiontech Se
01/06/202411:00UK RegulatoryInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)LSE:0A3MBiontech Se
29/05/202409:00UK RegulatoryBioNTech und CEPI erweitern Partnerschaft zur Stärkung des afrikanischen mRNA-Impfstoff-ÖkosystemsLSE:0A3MBiontech Se
29/05/202409:00UK RegulatoryBioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine EcosystemLSE:0A3MBiontech Se
21/05/202407:45UK RegulatoryBioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-KandidatenLSE:0A3MBiontech Se
21/05/202407:45UK RegulatoryBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024LSE:0A3MBiontech Se
17/05/202412:15UK RegulatoryAktionärinnen und Aktionäre stimmen auf der ordentlichen Hauptversammlung 2024 der BioNTech SE allen Tagesordnungspunkten zuLSE:0A3MBiontech Se
17/05/202412:15UK RegulatoryBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024LSE:0A3MBiontech Se
06/05/202407:45UK RegulatoryBioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur GeschäftsentwicklungLSE:0A3MBiontech Se
06/05/202407:45UK RegulatoryBioNTech Announces First Quarter 2024 Financial Results and Corporate UpdateLSE:0A3MBiontech Se
22/04/202407:45UK RegulatoryBioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen FortschrittLSE:0A3MBiontech Se
22/04/202407:45UK RegulatoryBioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024LSE:0A3MBiontech Se
07/04/202415:00UK RegulatoryDrei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem BauchspeicheldrüsenkrebsLSE:0A3MBiontech Se
07/04/202415:00UK RegulatoryThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic CancerLSE:0A3MBiontech Se
20/03/202407:15UK RegulatoryBioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateLSE:0A3MBiontech Se
20/03/202407:15UK RegulatoryBioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 sowie Informationen zur GeschäftsentwicklungLSE:0A3MBiontech Se
20/03/202407:00UK RegulatoryBioNTech beruft Annemarie Hanekamp als Chief Commercial Officer in den VorstandLSE:0A3MBiontech Se
20/03/202407:00UK RegulatoryBioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial OfficerLSE:0A3MBiontech Se
11/03/202408:45UK RegulatoryBioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-KandidatenLSE:0A3MBiontech Se
11/03/202408:45UK RegulatoryBioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024LSE:0A3MBiontech Se
07/03/202408:45UK RegulatoryBioNTech gibt geplanten Ruhestand von Sean Marett bekanntLSE:0A3MBiontech Se
07/03/202408:45UK RegulatoryBioNTech Announces Planned Retirement of Sean MarettLSE:0A3MBiontech Se
06/03/202408:45UK RegulatoryBioNTech veröffentlicht am 20. März 2024 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 und informiert über operativen FortschrittLSE:0A3MBiontech Se
06/03/202408:45UK RegulatoryBioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024LSE:0A3MBiontech Se
08/02/202407:45UK RegulatoryBioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-ProgrammeLSE:0A3MBiontech Se
08/02/202407:45UK RegulatoryBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs LSE:0A3MBiontech Se
31/01/202408:45UK RegulatoryBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305LSE:0A3MBiontech Se
31/01/202408:45UK RegulatoryBioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305LSE:0A3MBiontech Se
 Apresentando as notícias mais relevantes sobre:LSE:0A3M

Seu Histórico Recente

LSE
QK39
Morg.st.b.v 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados